Belara, 2 mg+0.03 mg 63 pcs

Pharmacodynamics:

Prolonged (more than 21 days) use of BELARA leads to decreased secretion of follicle stimulating hormone and luteinizing hormone and, consequently, suppression of ovulation, endometrial proliferation and its secretory transformation. At the same time the properties of cervical mucus change, which is accompanied by difficulty in the passage of sperm through the cervical canal and impaired sperm motility.

The component of BELARA, chlormadinone acetate, is a progestagen with anti-androgenic properties. Its action is based on the ability to replace androgens at specific receptors, eliminating and weakening the effect of endogenous and exogenous androgens. It takes 1.7 mg of chlormadinone acetate daily to completely suppress ovulation. The required dose per cycle is 25 mg.
BELARA’s other active ingredient, ethinyl estradiol, inhibits skin sweat gland secretion. It also significantly increases the production of globulin that binds sex hormones, thereby reducing the amount of free testosterone in the blood plasma.

Interacts with specialized estrogen receptors in the target organs (in the fallopian tubes, cervix, vagina, external genitalia, mammary ducts) and causes endometrial proliferation.

In addition to its reliable contraceptive properties, the positive effects of BELARA may be observed in menstrual cycle normalization, reduction of premenstrual syndrome, incidence of iron deficiency anemia, dysmenorrhea, functional ovarian cysts, ectopic pregnancy, endometrial and ovarian malignancies, certain forms of benign breast diseases and pelvic inflammatory diseases.

Pharmacokinetics

Chlormadinone acetate and ethinylestradiol are quickly and completely absorbed when the drug is taken orally. The maximum concentration of ethinylestradiol is reached after 1.5 hours. The maximum concentration of chlormadinone acetate is reached in 1-2 hours.

The elimination half-life of chloradinone acetate is approximately 34-39 h, of ethinylestradiol 12-14 h. Chlormadinone acetate metabolites are excreted by the kidneys and through the intestine in the ratio of 2:3.

The elimination half-life of ethinylestradiol is approximately 12-14 h.

The metabolites of ethinylestradiol are water-soluble sulfate or glucuron conjugation derivatives.

Ethinylestradiol metabolites are excreted by the kidneys and through the intestine at a ratio of 4:6.

Indications

Oral contraception.

Composition

One film-coated tablet contains

the active ingredients:

chlormadinone acetate 2 mg and ethinylestradiol 0.03 mg;

excipients:

povidone K 30 – 4.5 mg,

corn starch – 9.0 mg,

p> lactose monohydrate – 68.97 mg,

magnesium stearate – 0.5 mg

film coating:

Hypromellose 6 mPa.c – 1.115 mg,

Lactose monohydrate – 0.575 mg,

Macrogol 6000 – 0.279 mg,

Propylene glycol – 0.093 mg,

Talc – 0.371 mg,

Titanium dioxide dye, E 171 – 0.557 mg,

Red iron oxide (III) dye, E 172 – 0.01 mg.

How to take, the dosage

Belara pills are started on day 1 of your menstrual cycle and continued daily (preferably at the same time) for 21 days. Then take a 7-day break, during which time menstrual bleeding should start. After the 7-day break, you should resume taking the drug from the next blister, whether or not the menstrual-like bleeding has stopped.

If hormonal contraceptives were not used during the preceding menstrual cycle, the pills should be started on the first day of the normal menstrual cycle (the first day of menstruation). The contraceptive effect begins on the first day of taking the pill. If your period lasts more than one day, you should take the first pill on the 5th day of your period, regardless of whether bleeding has stopped or not. In this case, you should use additional, non-hormonal methods of contraception for the first 7 days. If more than 5 days have passed since the beginning of menstruation, it is recommended that the woman start taking the drug from the next menstrual cycle.

If you switch from another hormonal contraceptive with 21 active pills, you should finish taking all pills of the old package. The first pill of Belara must be taken the next day. There should be no interruption in taking the pills; the patient should not wait for the next menstrual cycle.

If you are switching from another hormonal contraceptive with 28 pills, the first Belara pill should be taken the day after taking the last active pill from the previous contraceptive package (that is, after taking 21 active pills). There should be no interruption in taking the pills; the patient should not wait for the next menstrual cycle.

When switching from contraceptives containing only gestagen (mini-pills), a woman may start taking Belara any day (without a break); when switching from the use of an implant containing gestagen, on the day it is removed; when switching from gestagens in injectable form, from the day when the next injection should have been made. In all cases, additional barrier methods of contraception should be used during the first 7 days of taking Belara.

After an abortion in the first trimester of pregnancy, you should start taking the drug immediately after the abortion. Additional methods of contraception are not necessary.

After childbirth, women who are not breastfeeding can start Belara on day 21-28 of the postpartum period. No additional contraceptive measures should be taken in this case. If the use of the drug in the postpartum period is started 28 days after delivery, additional contraceptive measures should be taken for 7 days. If a woman has had sexual intercourse, it is necessary to rule out pregnancy and wait for the next menstrual cycle before starting the use of the drug.

If the patient did not take the drug at the usual time and less than 12 hours have passed since the set time of taking the drug, the contraceptive effect of the drug remains, and the missed pill should be taken as soon as possible. The next pill should be taken at the prescribed time.

If more than 12 hours have elapsed since the prescribed time, the contraceptive effect of the drug may decrease. It is necessary to take the missed pill immediately and continue taking the drug at the usual time. It is necessary to use additional barrier methods of contraception for the next 7 days. If during these 7 days the pills in the package ran out, you should start taking pills from the next package immediately after completing the pills in the previous package, i.e. there is no break between the intake of pills from different packages. If there was no menstrual bleeding after taking the second package, pregnancy should be ruled out.

If vomiting or diarrhea occurs while taking Belara tablets, additional contraceptive methods are recommended because the contraceptive effect of the drug may be reduced due to incomplete absorption of its active ingredients in the intestine.
Tablets should be swallowed whole, selecting the tablet that is marked with the corresponding day of the week. The direction of the arrow on the package determines the choice of tablets.

Interaction

The interaction of ethinylestradiol, the estrogenic component of BELARA®, with other medicinal products may increase or decrease serum concentrations of ethinylestradiol. If long-term treatment with these drugs is necessary, you should switch to non-hormonal contraception.

Decreased serum ethinylestradiol concentrations may increase the frequency of breakthrough bleeding episodes, disrupt the cycle, and decrease the contraceptive efficacy of BELARA®. Increased serum concentrations of ethinylestradiol may increase the frequency and severity of side effects.

The following drugs/active ingredients may decrease serum ethinylestradiol concentrations:
– all drugs that increase gastrointestinal motility (e.g., metoclopramide) or impair adsorption (e.g., activated charcoal);

– Active agents that induce microsomal liver enzymes, such as rifampicin, rifabutin, barbiturates, antiepileptics (e.g., carbamazepine, oxcarbazepine, phenytoin and topiramate) anticonvulsant felbamate, phenylbutazone, griseofulvin, barbecsalone, primidone, modafinil, some protease inhibitors (e.g., ritonavir) and St John’s wort preparations;

– some antibiotics (e.g., ampicillin, tetracycline, rifampicin) – due to decreased enterohepatic circulation of estrogen.
When concomitant use of such drugs/active substances with BELARA® tablets, additional barrier methods of contraception should be used both during treatment and within 7 days after it. If active agents that reduce the concentration of ethinylestradiol in blood serum by induction of hepatic microsomal enzymes are taken, additional barrier methods (condom, spermicides) should be used for 28 days after the end of treatment.

The following drugs/active substances can increase the serum concentration of ethinylestradiol:

– active agents that inhibit ethinylestradiol sulfation in the intestinal wall, such as ascorbic acid or paracetamol;
– atorvastatin;
– agents that inhibit hepatic microsomal enzyme activity, such as antifungal imidazoles (such as fluconazole), indinavir or troleandomycin.
Ethinylestradiol can affect the metabolism of other substances:
-inhibit the activity of hepatic microsomal enzymes and, accordingly, increase the serum concentration of active substances such as diazepam (and other benzodiazepines metabolized through hydroxylation), cyclosporine, theophylline and prednisolone;
– induce glucuronidation in the liver and, accordingly, reduce serum concentrations of, for example, clofibrate, paracetamol, morphine and lorazepam.

The need for insulin and oral antidiabetic agents may change because of the drug’s effect on glucose tolerance.

Special Instructions

Smoking increases the risk of serious cardiovascular side effects of PDA, the risk increases with age and according to the number of cigarettes smoked and is more pronounced in women over the age of 35, women who smoke over 35 should use other methods of contraception.

The risk of serious conditions such as myocardial infarction, thrombosis/thromboembolism, stroke, and liver neoplasms increases with use of PDA.

Other risk factors such as hypertension, hyperlipidemia, obesity, and diabetes clearly increase the risk of morbidity and mortality.

If any of the above diseases/risk factors are present, the possible benefits of prescribing Belara® versus risks should be weighed and this should be discussed with the woman before she starts taking the drug. If these diseases or risk factors begin to appear or progress while taking this medication, you should see your doctor.

The doctor must decide if the drug should be stopped.

Thromboemboli and other vascular disease

It has been noted that there is an association between taking PDA and an increased risk of diseases caused by venous or arterial thromboembolism, such as myocardial infarction, cerebral stroke, deep vein thrombosis, or pulmonary embolism. These complications are rare.

PDA administration leads to an increased risk of venous thromboembolism (VTE). The risk of VTE is greatest during the first year of use. This risk is less than in pregnancy, where the rate of VTE is 60 per 100,000 pregnancies. VTE is fatal in 1-2% of cases. There are no data to assess the risk of VTE when taking Belara® compared to other PDAs.
The risk of venous thromboembolic complications increases when taking PDAs:

Contraindications

Combined oral contraception (COC) is contraindicated in the following cases. You should stop taking Belara immediately if any of the following symptoms occur:

Side effects

There may be adverse reactions of the following organs and systems:

Immune system.
Infrequent: hypersensitivity to the components of the drug including allergic skin reactions.

Metabolism.
Infrequent: changes in blood lipid composition including hypertriglyceridemia.
Rare: increased appetite.

Psycho-emotional sphere.
Often: depression, nervousness, irritability.
Infrequent: decreased libido.

Nervous system.
Often: dizziness, migraine (and/or its aggravation).

Visual organs.
Often: visual disturbances.
Rare: conjunctivitis, contact lens intolerance.
Hearing organs and vestibular system.
Rare: sudden hearing loss, tinnitus.

The cardiovascular system.
Frequently: increased arterial, blood pressure.
Rarely: hypertension, hypotension, cardiovascular collapse, varicose vein disease, venous thrombosis.

The digestive system.
Very common: nausea.
Frequent: vomiting.
Infrequent: abdominal pain, flatulence, diarrhea.

Skin and subcutaneous tissue.
Often: acne.
Infrequent: pigmentation disorders, chloasma, hair loss, dry skin, hyperhidrosis.
Rare: urticaria, eczema, erythema, skin itching, psoriasis aggravation, hypertrichosis.
Very rare: erythema nodosum.

Musculoskeletal system.
Often: feeling of heaviness.
Infrequent: back pain, muscle disorders.

Reproductive system and mammary glands.
Very Frequent: increased mucous vaginal discharge, dysmenorrhea, amenorrhea.
Frequent: lower abdominal pain.
Infrequent: galactorrhea, breast fibroadenoma, vaginal candidiasis.
Rare: breast enlargement, vulvovaginitis, menorrhea, premenstrual syndrome.

General disorders.
Often: fatigue, edema, weight gain.

The following adverse effects have also been reported with combined oral contraceptives (OCPs), including those containing 0.03 mg of ethinylestradiol and 2 mg of chlormadinone acetate:

– Increased risk of venous and arterial thromboembolism (e.g., venous thrombosis, pulmonary embolism, stroke, myocardial infarction). The risk may be increased by additional factors, see section “Special Precautions”.

– increased risk of biliary tract disease,

– in rare cases, increased risk of benign liver neoplasms (and even rarer – malignant liver neoplasms) and single cases may lead to life-threatening intra-abdominal bleeding (see also “Special Guidelines”).

– exacerbation of chronic inflammatory bowel diseases (Crohn’s disease, ulcerative colitis).

Overdose

In case of overdose of the drug, no severe toxic reactions are observed. When accidentally taking a large number of pills, nausea, vomiting, bloody discharge/vaginal bleeding may occur.

There is no specific antidote. Treatment is symptomatic. In rare cases, control of the parameters of water-electrolyte exchange and liver function is necessary.

Pregnancy use

Pregnancy: Use of Belara is contraindicated during pregnancy. Before you start using Belara, you should rule out the presence of pregnancy.

If you become pregnant while taking Belara, stop taking it immediately. The data available to date contain no information on the development of teratogenic or embryotoxic effects in women who have accidentally taken preparations containing estrogens and progesterones in the same combination as Belara during pregnancy.

Lactation: Belara is not recommended during breastfeeding because it reduces the amount of milk produced and changes its composition. Small amounts of the hormones and/or their metabolites that make up the contraceptive are excreted with breast milk and may affect a breast-fed baby.